COMPANY PROFILE

Revitope Oncology

Explore full profile

Developing a novel approach to cancer immunotherapy

Cambridge, United StatesFounded 2016Biotech & Life Sciences

Valuation $25–50M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Revitope Oncology

Revitope Oncology Inc., based in Cambridge, MA, and Shanghai, China, is pioneering the development of novel T cell engaging antibody circuits (TEAC) and Antibody Peptide Epitope Circuits (APEC) aimed at targeting tumors with high precision. The company operates in the immuno-oncology market, focusing on creating safer, life-changing medicines that restore hope for a healthy future beyond cancer. Revitope's core clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced cancer treatment solutions. The business model revolves around research and development, clinical trials, and partnerships with other biotech firms to bring their innovative therapies to market. Revenue is generated through licensing agreements, partnerships, and potential future sales of approved therapies.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Cambridge, United States
Employees: 7
Open positions: None listed
Dealroom signal: 27.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, UKSU, UKSU2010, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Dec 2020	$10M	$40M	Shanghai Junshi Bio	—
SEED✓Equity / VC	Feb 2016	$8.5M	$34M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Revitope Oncology website traffic

Latest recorded traffic for Revitope Oncology is 1K monthly website visits, up 733.3% over the last three months. Revitope Oncology's team grew 0% over the past year.

Latest monthly visits1K 3-month web change+733.3% 1-year team growth0%

Monthly website visitsOct 2017–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MBMyricx BioNovel antibody-drug conjugate payloads for cancer treatment	London, United Kingdom	Acquired	38	$164M	$1.1B
MTMonte Rosa TherapeuticsDeveloping next-generation small molecule protein degraders to treat cancer and beyond	Boston, United States	Operational
ATArgonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation	Oxford, United Kingdom	Acquired
KIKinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection	Macclesfield, United Kingdom	Operational
MAMacomicsDeveloping precision medicines to modulate macrophages for the treatment of cancer	Edinburgh, United Kingdom	Operational
TATagomicsMultiomic platform for disease biomarker discovery and diagnostics	Cambridge, United Kingdom	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
BIBioCaptivaNovel liquid biopsy device for cancer diagnostics	St Andrews, United Kingdom	Operational